MCID: PTT007
MIFTS: 59

Pituitary Cancer

Categories: Cancer diseases, Endocrine diseases, Eye diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Pituitary Cancer

MalaCards integrated aliases for Pituitary Cancer:

Name: Pituitary Cancer 11 19 14 16
Pituitary Carcinoma 11 19 58 5 14 71
Malignant Neoplasm of Pituitary Gland 71
Malignant Tumor of Pituitary Gland 11
Carcinoma of the Pituitary Gland 11
Neoplasm of the Pituitary Gland 28
Malignant Pituitary Neoplasm 11
Neoplasm of Pituitary Gland 11
Pituitary Gland Neoplasm 11
Pituitary Gland Cancer 11
Pituitary Neoplasms 43
Pituitary Neoplasm 11

Characteristics:


Prevelance:

Pituitary Carcinoma: <1/1000000 (Europe, Austria, Belgium, Bulgaria, Czech Republic, Estonia, Finland, Germany, Ireland, Italy, Latvia, Lithuania, Malta, Norway, Portugal, Slovakia, Slovenia, Spain, Switzerland, Netherlands, United Kingdom) 1-9/1000000 (Europe, Croatia, Iceland, Poland) 58

Age Of Onset:

Pituitary Carcinoma: All ages 58

Classifications:



External Ids:

Disease Ontology 11 DOID:1785 DOID:4916
MeSH 43 D010911
ICD10 31 C75.1
ICD10 via Orphanet 32 C75.1
UMLS via Orphanet 72 C0346300
Orphanet 58 ORPHA300385
UMLS 71 C0032019 C0346300 C0496842

Summaries for Pituitary Cancer

GARD: 19 A rare pituitary tumor characterized by the presence of a pituitary adenoma that has metastasized either within the central nervous system, or to distant sites. The vast majority of pituitary carcinomas are hormonally active, most frequently with ACTH or prolactin production. The most common clinical symptoms are diabetes insipidus, optic nerve dysfunction, anterior pituitary dysfunction, palsy of cranial nerves III, IV, or VI, and headaches, although patients may also be asymptomatic. The tumors behave aggressively, and prognosis is poor.

MalaCards based summary: Pituitary Cancer, also known as pituitary carcinoma, is related to silent pituitary adenoma and functionless pituitary adenoma. An important gene associated with Pituitary Cancer is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Signal Transduction and DNA Damage. The drugs Prednisone and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include pituitary gland located at the base of the brain, pituitary and thyroid, and related phenotypes are pituitary carcinoma and headache

Orphanet: 58 A rare pituitary tumor characterized by the presence of a pituitary adenoma that has metastasized either within the central nervous system, or to distant sites. The vast majority of pituitary carcinomas are hormonally active, most frequently with ACTH or prolactin production. The most common clinical symptoms are diabetes insipidus, optic nerve dysfunction, anterior pituitary dysfunction, palsy of cranial nerves III, IV, or VI, and headaches, although patients may also be asymptomatic. The tumors behave aggressively, and prognosis is poor.

Disease Ontology: 11 An endocrine gland cancer located in the pituitary gland located at the base of the brain.

Related Diseases for Pituitary Cancer

Diseases related to Pituitary Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 226)
# Related Disease Score Top Affiliating Genes
1 silent pituitary adenoma 32.4 MEN1 AIP
2 functionless pituitary adenoma 32.3 SST POMC MEG3
3 pituitary adenoma 1, multiple types 32.2 SST PRL MEN1 AIP
4 pituitary adenoma 3, multiple types 32.2 USP8 GNAS
5 prolactin producing pituitary tumor 31.9 TP53 SSTR5 PRL POMC MGMT MEN1
6 hormone producing pituitary cancer 30.8 USP8 SSTR5 SSTR2 SST PRL PRKAR1A
7 chromophobe adenoma 30.4 PRL POMC
8 hyperprolactinemia 30.3 SST PRL POMC GNAS
9 paraganglioma 30.1 SSTR2 SST POMC MEN1
10 hypopituitarism 30.1 TBX19 PRL POMC
11 pituitary apoplexy 30.0 SST PRL POMC AIP
12 pituitary-dependent cushing's disease 29.9 USP8 SST PRL POMC
13 hyperthyroidism 29.8 SST PRL POMC GNAS
14 pheochromocytoma 29.8 SST PRL POMC MEN1 MEG3
15 cowden syndrome 29.7 TP53 PRKAR1A PMS2 MEN1
16 neuroendocrine tumor 29.7 SSTR2 SST POMC MEN1 CDKN1B
17 pituitary tumors 29.7 SSTR5 SST PTTG1 PRL MEN1 GNAS
18 acromegaly 29.7 SSTR5 SSTR2 SST PRL POMC MEN1
19 inherited cancer-predisposing syndrome 29.6 TP53 PRKAR1A PMS2 MEN1 CDKN1B AIP
20 bap1 tumor predisposition syndrome 29.6 TP53 PRKAR1A PMS2 MEN1 CDKN1B AIP
21 lynch syndrome 29.6 TP53 PMS2 MGMT MEN1 GNAS
22 meningioma, familial 29.6 TP53 SSTR5 SSTR2 SST PRL PRKAR1A
23 prolactinoma 29.5 SSTR5 SSTR2 SST PTTG1 PRL PRKAR1A
24 multiple endocrine neoplasia 29.5 SST PRL PRKAR1A POMC MEN1 GNAS
25 nelson syndrome 29.4 USP8 TBX19 SSTR5 SST PRL POMC
26 tsh producing pituitary tumor 29.3 USP8 TBX19 SSTR5 SST PRL POMC
27 acth-secreting pituitary adenoma 29.3 USP8 TBX19 SSTR5 SSTR2 SST PRL
28 multiple endocrine neoplasia, type i 29.1 SSTR2 SST PRL PRKAR1A POMC MEN1
29 conn's syndrome 28.9 USP8 TP53 TBX19 SST PRL PRKAR1A
30 pituitary adenoma 28.1 USP8 SSTR5 SSTR2 SST PTTG1 PRL
31 adenoma 28.0 USP8 TP53 SSTR5 SSTR2 SST PTTG1
32 functioning pituitary adenoma 27.9 USP8 TBX19 SSTR5 SSTR2 SST PRL
33 pituitary gland disease 27.9 USP8 TBX19 SSTR5 SSTR2 SST PTTG1
34 posterior pituitary gland neoplasm 11.4
35 malignant thyroid stimulating hormone producing neoplasm of pituitary gland 11.3
36 malignant acth producing neoplasm of pituitary gland 11.3
37 pituitary adenoma 2, growth hormone-secreting 11.2
38 pituitary adenoma 5, multiple types 11.2
39 non-functioning pituitary adenoma 11.2
40 pituitary blastoma 11.0
41 bronchial adenomas/carcinoids childhood 10.4 SST POMC
42 tuberculum sellae meningioma 10.4 PRL POMC
43 null pituitary adenoma 10.4 MEN1 AIP
44 appendix carcinoid tumor 10.4 POMC PMS2
45 sella turcica neoplasm 10.4 PRL POMC
46 non-functioning pancreatic endocrine tumor 10.4 SST MEN1
47 gastric gastrinoma 10.4 SST MEN1
48 pancreatic somatostatinoma 10.4 SST MEN1
49 abducens palsy 10.3 PRL POMC
50 pancreatic cholera 10.3 SST MEN1

Graphical network of the top 20 diseases related to Pituitary Cancer:



Diseases related to Pituitary Cancer

Symptoms & Phenotypes for Pituitary Cancer

Human phenotypes related to Pituitary Cancer:

58 30 (show all 24)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pituitary carcinoma 58 30 Obligate (100%) Obligate (100%)
HP:0011763
2 headache 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002315
3 pituitary prolactin cell adenoma 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0006767
4 increased circulating acth level 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003154
5 pituitary corticotropic cell adenoma 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0008291
6 malignant neoplasm of the central nervous system 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0100836
7 increased circulating prolactin concentration 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000870
8 hemianopia 58 30 Frequent (33%) Frequent (79-30%)
HP:0012377
9 hypopituitarism 58 30 Frequent (33%) Frequent (79-30%)
HP:0040075
10 progressive visual field defects 58 30 Frequent (33%) Frequent (79-30%)
HP:0007987
11 enlarged pituitary gland 58 30 Frequent (33%) Frequent (79-30%)
HP:0012505
12 reduced visual acuity 30 Frequent (33%) HP:0007663
13 ataxia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001251
14 hearing impairment 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000365
15 pituitary growth hormone cell adenoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011760
16 spinal cord lesion 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100561
17 elevated circulating growth hormone concentration 30 Occasional (7.5%) HP:0000845
18 diabetes insipidus 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000873
19 pituitary gonadotropic cell adenoma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0011759
20 pituitary thyrotropic cell adenoma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0011762
21 growth hormone excess 58 Occasional (29-5%)
22 mildly reduced visual acuity 58 Frequent (79-30%)
23 hyperpituitarism 58 Occasional (29-5%)
24 abnormality of central motor function 58 Occasional (29-5%)

GenomeRNAi Phenotypes related to Pituitary Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 MEN1 TP53

MGI Mouse Phenotypes related to Pituitary Cancer:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 AIP CDKN1B GNAS MEN1 MGMT PMS2
2 nervous system MP:0003631 10.22 CDKN1B GNAS MEN1 MGMT POMC PRL
3 neoplasm MP:0002006 10.21 AIP CDKN1B GNAS MEN1 MGMT PMS2
4 growth/size/body region MP:0005378 10.21 AIP CDKN1B GNAS MEG3 MEN1 POMC
5 liver/biliary system MP:0005370 10.2 AIP CDKN1B GNAS MEG3 MEN1 PMS2
6 endocrine/exocrine gland MP:0005379 10.13 AIP CDKN1B GNAS MEN1 MGMT PMS2
7 no phenotypic analysis MP:0003012 10.04 CDKN1B GNAS MGMT POMC PTTG1 SST
8 adipose tissue MP:0005375 9.98 CDKN1B GNAS POMC PRKAR1A PTTG1 SST
9 pigmentation MP:0001186 9.92 CDKN1B POMC PRKAR1A TBX19 TP53
10 embryo MP:0005380 9.91 AIP CDKN1B GNAS MEG3 MEN1 PRKAR1A
11 mortality/aging MP:0010768 9.8 AIP CDKN1B GNAS MEG3 MEN1 MGMT
12 digestive/alimentary MP:0005381 9.76 CDKN1B GNAS MEN1 PMS2 PRKAR1A SST
13 integument MP:0010771 9.28 AIP CDKN1B GNAS POMC PRKAR1A PRL

Drugs & Therapeutics for Pituitary Cancer

Drugs for Pituitary Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Acetaminophen Approved Phase 4 103-90-2 1983
3
Ibuprofen Approved Phase 4 15687-27-1 3672
4
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
5
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
6
Morphine Approved, Investigational Phase 4 57-27-2 5288826
7
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
8
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
9
Bromocriptine Approved, Investigational, Withdrawn Phase 4 25614-03-3 31101
10
Cefuroxime Approved Phase 4 55268-75-2 5479529
11
Cefdinir Approved Phase 4 91832-40-5 6915944
12
Cefazolin Approved Phase 4 25953-19-9 33255
13
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
14
Sulfamethoxazole Approved Phase 4 723-46-6 5329
15
Clindamycin Approved, Vet_approved Phase 4 18323-44-9, 24729-96-2 29029
16
Quinagolide Approved, Investigational Phase 4 87056-78-8
17
Cabergoline Approved Phase 4 81409-90-7 54746
18
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
19
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605 16129706
20
Pasireotide Approved Phase 4 396091-73-9 56841596 9941444
21
Lactitol Approved, Investigational Phase 4 585-86-4 157355
22
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
23
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
25
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
26 Antineoplastic Agents, Hormonal Phase 4
27 Gastrointestinal Agents Phase 4
28 Antirheumatic Agents Phase 4
29 Cyclooxygenase Inhibitors Phase 4
30 Anti-Inflammatory Agents, Non-Steroidal Phase 4
31 Analgesics, Opioid Phase 4
32 Narcotics Phase 4
33 Folate Phase 4
34 Vitamin B9 Phase 4
35 Vitamin B Complex Phase 4
36 Anti-Bacterial Agents Phase 4
37 Antibiotics, Antitubercular Phase 4
38 Folic Acid Antagonists Phase 4
39 Cephalosporins Phase 4
40
Cefuroxime axetil Phase 4 3379942
41 Anti-Infective Agents Phase 4
42 Antiprotozoal Agents Phase 4
43 Antiparasitic Agents Phase 4
44 Antimalarials Phase 4
45 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
46 Cytochrome P-450 Enzyme Inhibitors Phase 4
47
Clindamycin phosphate Phase 4 32603
48 Clindamycin palmitate Phase 4
49 Cardiotonic Agents Phase 4
50 Sympathomimetics Phase 4

Interventional clinical trials:

(show top 50) (show all 135)
# Name Status NCT ID Phase Drugs
1 Effect of Dexmedetomidine as Anesthetic Coadjuvant on Plasmatic Cortisol Response in Transsphenoidal Surgery for Pituitary Tumors Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
2 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
3 Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach Unknown status NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
4 Randomized, Double-Blind, Placebo-Controlled Trial Comparing Opioid-Sparing and Opioid-Containing Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor;IV Placebo
5 Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study Completed NCT01371643 Phase 4 Octreotide LAR
6 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
7 PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials Recruiting NCT04107480 Phase 4 Dopamine Agonists
8 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline
9 The Effects of Infraorbital Nerve Block With Dexmedetomidine Added to Bupivacaine on Fentanyl Requirement During Endoscopic Transsphenoidal Approach to Remove Pituitary Tumor: Prospective Randomized Double Blinded Control Study Not yet recruiting NCT04785222 Phase 4 dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine
10 Dopamine Agonist Cabergoline in Residual Clinically Nonfunctioning Pituitary Adenoma After Transphenoidal Surgery: A Single Center, Open Label and Randomized Clinical Trial Completed NCT03271918 Phase 3 Cabergoline
11 Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
12 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
13 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial Recruiting NCT02288962 Phase 3 cabergoline
14 Comparison Between Hemodynamic Effect of Bilateral Infraorbital Block Versus Intranasal Application of Bupivacaine in Patients Undergoing Transsphenoidal Pituitary Adenoma Resection.A Comparative Randomized Controlled Study Recruiting NCT05301634 Phase 3
15 Radiotherapy Plus Concomitant Temozolomide for Refractory Pituitary Adenomas,A Randomized,Double-blind, Placebo-controlled Phase II Trial Not yet recruiting NCT04244708 Phase 2, Phase 3 Radiotherapy plus temozolomide
16 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma From an Endocrinological Point of View (MERGE Study): a Randomized, Phase 3 Trial Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
17 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Terminated NCT02419664 Phase 3 Gallium-68 DOTATOC PET
18 A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Completed NCT01689727 Phase 2 Technetium Tc 99m EC20
19 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed NCT00939523 Phase 2 Lapatinib
20 Sandostatin LAR vs. Surgery in Acromegalics With Macroadenoma Completed NCT00001860 Phase 2 Sandostatin LAR Depot versus transsphenoidal surgery
21 An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma Completed NCT01283542 Phase 2 Pasireotide LAR
22 Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Aggressive Pituitary Tumors Recruiting NCT04042753 Phase 2 Ipilimumab;Nivolumab
23 The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease Recruiting NCT04339751 Phase 2 Vorinostat
24 A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas Not yet recruiting NCT04335357 Phase 2 TBR-760;Placebo
25 Effect of Dexmedetomidine on Intraoperative Neuroendocrine Stress Response and Early Postoperative Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Tumor Surgery Not yet recruiting NCT05005715 Phase 2 Dexmedetomidine;normal saline
26 Pilot Study of Pasireotide LAR Treatment of Silent Corticotrophin Pituitary Tumors and Effects on Plasma Levels of POMC Terminated NCT02749227 Phase 2 Pasireotide LAR
27 An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
28 Rosiglitazone (Peroxisome Proliferating Activating Receptor-gamma {PPAR-y} Ligand) Treatment of Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
29 Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas Terminated NCT03930771 Phase 2 Capecitabine;Temozolomide
30 A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma Withdrawn NCT04106843 Phase 2 Lutetium Lu 177 Dotatate
31 Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Metastatic or Incurable Neuroendocrine Tumors Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
32 An Open Label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Temozolomide Treatment in Patients With Invasive Pituitary Tumors Withdrawn NCT00601289 Phase 2 temozolomide
33 Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery: A Double-Blind Randomized Controlled Trial Withdrawn NCT04863339 Phase 2 Tranexamic acid;Placebo
34 Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma Withdrawn NCT01203618 Phase 2 Farletuzumab
35 Detection of Functioning Pituitary Microadenoma With Inconclusive MRI Findings: PET/MRI Versus PET/CT Unknown status NCT03404414 Phase 1 18F-FDG
36 Detection of Pituitary Neuroendocrine Tumor (PitNET) Tissue During Endoscopic Transsphenoidal Surgery Using Bevacizumab-800CW Recruiting NCT04212793 Phase 1 Bevacizumab-IRDye800CW
37 Imaging of Patients With Malignant Brain Tumors Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers: A Phase 1 Microdosing Study Active, not recruiting NCT03465618 Phase 1 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging
38 A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma Terminated NCT02629549 Phase 1 OTL38
39 A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
40 Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Unknown status NCT01775332
41 A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas Unknown status NCT03309319 Rosiglitazone
42 Extended Support Within a Person-centred Practice After Surgery: a Quasi- Experimental Study for Persons With Pituitary Tumours Unknown status NCT03927183
43 Molecular Imaging of Pituitary Adenomas Unknown status NCT03815838
44 The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of Nonfunctioning Pituitary Adenoma Unknown status NCT03714763 Drug treatment
45 Withholding Hydrocortisone vs Routine Use of Hydrocortisone During Peri-operation in Pituitary Adenoma Patients With Intact Hypothalamus-Pituitary-Adrenal Axis: Randomized Controlled Trial to Assess Safety and Complications Unknown status NCT04621565 Normal saline;Hydrocortisone
46 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) vs. Tramadol in Pain Management After Transnasal Transsphenoidal Surgery Among Patients With Pituitary Adenomas: A Prospective Randomized Controlled Trial Unknown status NCT04611685 NSAID;Tramadol
47 Comparison of The Effects of Sevoflurane, Desflurane and Total Intravenous Anaesthesia on Pulmonary Function Tests in Patients Undergoing Endoscopic Endonasal Transsphenoidal Surgery of Pituitary Gland Unknown status NCT02709863 Sevoflurane;Desflurane;Propofol
48 Impact of Nasoseptal Flap Harvest Technique on Olfaction Following Endoscopic Transsphenoidal Pituitary Surgery: A Single-blinded Randomized Controlled Trial Unknown status NCT03773705
49 Prospective MRI Evaluation of Cavernous Sinus Invasion by Pituitary Adenoma Using Deep Learning Based Denoising Unknown status NCT04268251
50 The Effect of Silastic Stenting on Post-Operative Intra-Nasal Re-Mucosalization Unknown status NCT03282058

Search NIH Clinical Center for Pituitary Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Octreotide
Octreotide Acetate

Cochrane evidence based reviews: pituitary neoplasms

Genetic Tests for Pituitary Cancer

Genetic tests related to Pituitary Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Pituitary Gland 28

Anatomical Context for Pituitary Cancer

Organs/tissues related to Pituitary Cancer:

FMA: Pituitary Gland Located At The Base Of The Brain
MalaCards : Pituitary, Thyroid, Brain, Spinal Cord, Hypothalamus, Heart, Lymph Node

Publications for Pituitary Cancer

Articles related to Pituitary Cancer:

(show top 50) (show all 402)
# Title Authors PMID Year
1
Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients. 62
36161330 2022
2
Pituitary carcinoma: A cytopathologic dilemma when metastatic to cervical lymph nodes. 62
36468310 2022
3
Metabolomics-A Tool to Find Metabolism of Endocrine Cancer. 62
36422294 2022
4
Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours. 62
35938916 2022
5
An aggressive lactotroph pituitary tumor in a young male: A pituitary carcinoma without metastasis. 62
35575415 2022
6
Paraneoplastic cast nephropathy associated with malignant prolactinoma: A case report and literature review. 62
35536097 2022
7
Pituitary Carcinoma Diagnosis and Survival Improvement, with Affordable Care Act Correlation: A SEER Database Study. 62
35769806 2022
8
Delayed Craniospinal Metastasis of Aggressive Nonfunctioning Pituitary Adenomas as Pituitary Carcinomas. 62
35832993 2022
9
Pituitary adenoma & nuclear medicine: Recent outcomes and ongoing developments. 62
36334843 2022
10
Brain Tumor Detection and Classification Using Cycle Generative Adversarial Networks. 62
35137330 2022
11
Pituitary blastoma, expanding the spectrum of newly recognized entities. A case report. 62
35435381 2022
12
ACTH-secreting pituitary carcinoma with TP53, NF1, ATRX and PTEN mutations Case report and review of the literature. 62
35171439 2022
13
Overview of the 2022 WHO Classification of Pituitary Tumors. 62
35291028 2022
14
Corticotroph pituitary carcinoma with skeletal metastases masquerading as ectopic ACTH syndrome: a long and winding road to diagnosis. 62
35319488 2022
15
A Rare Case of Pituitary Carcinoma With Bone Metastases: 68Ga-DOTATATE PET/CT Findings. 62
35025796 2022
16
Pituitary carcinoma as a rare cause of liver metastases successfully treated with temozolomide. 62
34935323 2022
17
Adrenocorticotropic Hormone Secreting Pituitary Carcinoma: Rare, Durable Response to Concurrent Chemotherapy and Reirradiation With a Review of the Literature. 62
34849427 2022
18
Distant Pituitary Adenoma Spread: A Systematic Review and Report of 2 Cases. 62
35030115 2022
19
Cervical Nodal Metastatic Pituitary Carcinoma: A Case Report. 62
32744903 2022
20
Pituitary Carcinoma in a Patient with Cowden Syndrome. 62
35110519 2022
21
COVID-19 and Cushing's disease in a patient with ACTH-secreting pituitary carcinoma. 62
35229722 2022
22
Non-functional recurrent pituitary adenoma with intracranial metastasis-Pituitary carcinoma: A case report and review of the literature. 62
33652067 2022
23
Pituitary carcinoma - case series and review of the literature. 62
36157469 2022
24
Cytomorphology of pituitary carcinoma metastatic to liver diagnosed by fine-needle aspiration: A rare case report and review of literature. 62
36128468 2022
25
Comprehensive clinical analysis of patients with primary malignant tumor of pituitary gland: A population-based study. 62
36329977 2022
26
A Pituitary Carcinoma Patient With Cerebrospinal Fluid Dissemination Showing a Good Response to Temozolomide Combined With Whole-Brain and Spinal Cord Radiotherapy: A Case Report and Literature Review. 62
35903687 2022
27
Immune-checkpoint inhibitors in pituitary malignancies. 62
34348358 2022
28
Cranial and Spinal Metastasis of a Nonfunctioning Pituitary Adenoma: Report of a Case. 62
34856620 2021
29
68Ga-DOTATATE PET/CT in Pituitary Carcinoma. 62
34269734 2021
30
Aggressive pituitary tumours and pituitary carcinomas. 62
34493834 2021
31
Should pituitary carcinoma be treated using a NET-like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy. 62
34845727 2021
32
Metastases to the Pituitary Gland: Histological Patterns of Spread and Review of the Literature. 62
34559240 2021
33
Primary Tumors of the Pituitary Gland: Radiologic-Pathologic Correlation. 62
34597177 2021
34
Evolution of a refractory prolactin-secreting pituitary adenoma into a pituitary carcinoma: report of a challenging case and literature review. 62
34715828 2021
35
Pituitary adenoma…nomen omen? 62
34114192 2021
36
Role of metformin and other metabolic drugs in the prevention and therapy of endocrine-related cancers. 62
34311387 2021
37
Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma. 62
34466766 2021
38
Growth hormone secreting pituitary carcinomas: Case report and review of literature. 62
34607164 2021
39
Invasive ACTH-producing pituitary gland neoplasm secondary to MSH2 mutation. 62
33866195 2021
40
Aggressive pituitary adenoma in the context of Lynch syndrome: a case report and literature review on this rare coincidence. 62
34431732 2021
41
Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors. 62
33866514 2021
42
Pituitary adenoma or pituitary neuroendocrine tumor: a narrative review of controversy and perspective. 62
35116513 2021
43
Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? 62
33604494 2021
44
HIV and the Pituitary Gland: Clinical and Biochemical Presentations. 62
34054243 2021
45
Clinical Implications of the New WHO Classification 2017 for Pituitary Tumors. 62
33690870 2021
46
Tumor invasion to the spinal region after primary surgery: A case report. 62
34760107 2021
47
Recent Understanding and Future Directions of Recurrent Corticotroph Tumors. 62
33986726 2021
48
Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach. 62
34220707 2021
49
A Silent Corticotroph Pituitary Carcinoma: Lessons From an Exceptional Case Report. 62
34992581 2021
50
Stereotactic Radiosurgery for Pituitary Carcinoma. 62
34191060 2021

Variations for Pituitary Cancer

ClinVar genetic disease variations for Pituitary Cancer:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PMS2 NM_000535.7(PMS2):c.137G>T (p.Ser46Ile) SNV Likely Pathogenic
9245 rs121434629 GRCh37: 7:6045549-6045549
GRCh38: 7:6005918-6005918

Cosmic variations for Pituitary Cancer:

8 (show top 50) (show all 123)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM86624499 RB1 pituitary,NS,adenoma,ACTH-FSH-GH-LH-PRL c.1861C>A p.R621S 13:48456250-48456250 19
2 COSM105721710 HRAS pituitary,NS,carcinoma,ACTH c.52G>A p.A18T 11:534271-534271 19
3 COSM91331451 HRAS pituitary,NS,carcinoma,ACTH c.52G>A p.A18T 11:534271-534271 19
4 COSM101967535 HRAS pituitary,NS,carcinoma,ACTH c.52G>A p.A18T 11:534271-534271 19
5 COSM112989145 HRAS pituitary,NS,carcinoma,ACTH c.52G>A p.A18T 11:534271-534271 19
6 COSM101951932 HRAS pituitary,NS,carcinoma,ACTH c.52G>A p.A18T 11:534271-534271 19
7 COSM150337228 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 19
8 COSM151605250 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 19
9 COSM150962042 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 19
10 COSM151491351 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 19
11 COSM105887915 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 19
12 COSM110179104 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 19
13 COSM150547790 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 19
14 COSM150961028 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 19
15 COSM111910236 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 19
16 COSM102452270 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 19
17 COSM150526110 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 19
18 COSM151827775 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 19
19 COSM150088294 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 19
20 COSM102412283 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 19
21 COSM110181025 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 19
22 COSM150300123 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 19
23 COSM146902958 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 19
24 COSM150454007 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 19
25 COSM151356165 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.106G>C p.A36P 3:41224639-41224639 19
26 COSM150480970 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 19
27 COSM150141897 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 19
28 COSM151979920 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 19
29 COSM151836221 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 19
30 COSM111893529 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 19
31 COSM150660304 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 19
32 COSM146245709 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 19
33 COSM111894601 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 19
34 COSM150867955 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 19
35 COSM151353823 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.106G>C p.A36P 3:41224639-41224639 19
36 COSM111038093 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 19
37 COSM102485110 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 19
38 COSM151345590 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 19
39 COSM150868805 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 19
40 COSM151592258 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 19
41 COSM150274829 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 19
42 COSM102450402 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 19
43 COSM102380394 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 19
44 COSM150827985 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 19
45 COSM151559313 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 19
46 COSM110212608 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 19
47 COSM150452305 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 19
48 COSM151343442 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 19
49 COSM151344333 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 19
50 COSM151570765 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 19

Expression for Pituitary Cancer

Search GEO for disease gene expression data for Pituitary Cancer.

Pathways for Pituitary Cancer

Pathways related to Pituitary Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.74 USP8 TP53 SSTR5 SSTR2 SST PRKAR1A
2 12.09 TP53 PTTG1 MGMT CDKN1B
3 11.39 TBX19 POMC GNAS
4 11.22 TP53 PRL POMC
5 10.96 TP53 MIR93 CDKN1B

GO Terms for Pituitary Cancer

Biological processes related to Pituitary Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to xenobiotic stimulus GO:0009410 9.61 TP53 SST PMS2 MGMT CDKN1B
2 somatostatin signaling pathway GO:0038170 9.46 SSTR5 SSTR2
3 negative regulation of cell population proliferation GO:0008285 9.44 TP53 SSTR5 SSTR2 SST MIR93 MEN1

Molecular functions related to Pituitary Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 somatostatin receptor activity GO:0004994 8.92 SSTR5 SSTR2

Sources for Pituitary Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....